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Methylglyoxal (MG) is a metabolite of glucose that may contribute to peripheral
neuropathy and pain in diabetic patients. MG increases intracellular calcium in sensory
neurons and produces behavioral nociception via the cation channel transient receptor
potential ankyrin 1 (TRPA1). However, rigorous characterization of an animal model of
methylglyoxal-evoked pain is needed, including testing whether methylglyoxal promotes
negative pain affect. Furthermore, it remains unknown whether methylglyoxal is sufficient
to activate neurons in the spinal cord dorsal horn, whether this requires TRPA1, and if
the calcium-sensitive adenylyl cyclase 1 isoform (AC1) contributes to MG-evoked pain.
We administered intraplantar methylglyoxal and then evaluated immunohistochemical
phosphorylation of extracellular signal-regulated kinase (p-ERK) and multiple pain-like
behaviors in wild-type rats and mice and after disruption of either TRPA1 or AC1.
Methylglyoxal produced conditioned place avoidance (CPA) (a measure of affective
pain), dose-dependent licking and lifting nociceptive behaviors, hyperalgesia to heat
and mechanical stimulation, and p-ERK in the spinal cord dorsal horn. TRPA1
knockout or intrathecal administration of a TRPA1 antagonist (HC030031) attenuated
methylglyoxal-evoked p-ERK, nociception, and hyperalgesia. AC1 knockout abolished
hyperalgesia but not nociceptive behaviors. These results indicate that intraplantar
administration of methylglyoxal recapitulates multiple signs of painful diabetic neuropathy
found in animal models of or patients with diabetes, including the activation of spinal
nociresponsive neurons and the potential involvement of a TRPA1-AC1 sensitization
mechanism. We conclude that administration of MG is a valuable model for investigating
both peripheral and central components of a MG-TRPA1-AC1 pathway that contribute
to painful diabetic neuropathy.
Keywords: methylglyoxal, TRPA1, AC1, pain, diabetes, peripheral, neuropathy
INTRODUCTION
Circulating levels of methylglyoxal (MG) are correlated with neuropathic pain in both patients
with diabetes and in rodent models of type 1 diabetes (Bierhaus et al., 2012; Sveen et al., 2013;
Huang et al., 2016). Hindpaw administration of MG is sufficient to produce pain-related behaviors
in mice (Bierhaus et al., 2012; Andersson et al., 2013; Huang et al., 2016; Viisanen et al., 2016)
and so is a promising approach to investigation of the mechanisms of diabetic neuropathic pain.
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Because a systematic evaluation of this model is lacking,
we sought to characterize the relationship between MG
concentration and the extent of multiple types of pain-like
behaviors and signs of spinal pain transmission following MG
administration. Therefore, in addition to behavior, we test the
hypothesis that intraplantar injection of MG evokes activation of
spinal nociresponsive neurons by evaluating the phosphorylation
of extracellular signal-regulated kinase (p-ERK) in the spinal
cord dorsal horn. P-ERK is an established marker of pain-
related central sensitization (Ji et al., 1999, 2009; Gao and Ji,
2009) and is exacerbated in conditions of peripheral nerve injury
(Morgenweck et al., 2013), inflammation (Corder et al., 2013),
and type 2 diabetes (Griggs et al., 2016).
Transient receptor potential ankyrin 1 (TRPA1), a cation
channel that is predominantly expressed in peripheral
nociceptors, is thought to mediate neuropathic pain in the
streptozotocin model of type 1 diabetes (Wei et al., 2009; Huang
et al., 2016). Disruption of TRPA1 is reported to attenuate
MG-evoked calcium responses in in vitro sensory neurons and
nociceptive behavior in vivo (Eberhardt et al., 2012; Koivisto
et al., 2012; Andersson et al., 2013). Using our new model of
MG-evoked hypersensitivity and p-ERK activation, we tested the
hypothesis that TRPA1 mediates hyperalgesia and spinal neuron
activation after intraplantar injection of MG.
Adenylyl cyclase 1 (AC1) is a key modulator of pain plasticity
in the central nervous system (Xia and Storm, 1997; Zhuo,
2012). An adenylyl cyclase signaling pathway in the spinal cord
contributes to pain-like behavior in Zucker Diabetic Fatty rats
(Feng et al., 2016), which also exhibit elevated MG (Griggs
et al., 2016). However, it is unknown whether the AC1 isoform
contributes to MG-related pain. Because MG-TRPA1 activity
produces a calcium response in sensory neurons (Eberhardt et al.,
2012; Andersson et al., 2013), and the AC1 isoform is activated
by calcium, we hypothesized that pain-like behavior produced by
MG-TRPA1 activity requires AC1.
METHODS
Animals
Sprague-Dawley rats (CD-IGS) weighing 300–450 g at the time
of behavioral procedures were obtained from Charles River
Laboratories, Inc. (Wilmington, MA). TRPA1 knockout (−/−)
and wild-type littermates (+/+) mice were provided by Dr.
Gregory Frolenkov (Department of Physiology, University of
Kentucky, Lexington, KY), courtesy of Drs. Kelvin Kwan and
David Corey (Harvard University, Cambridge, MA), and were
used to set up a TRPA1 knockout mouse breeding colony.
AC1−/− mice were provided by Dr. Daniel Storm (Washington
University, Seattle, WA, USA) and were used to set up an AC1
knockout colony. TRPA1−/− and AC1−/− congenic knockout
mouse lines were maintained on a C57BL/6J (JAX Mice, The
Jackson Laboratory, Bar Harbor, ME; RRID:IMSR_JAX:000664)
background with genotypes confirmed by tail-snip PCR.
Animals were housed in a temperature and
humidity controlled room on a 12-h light/12-h dark
(rats lights on 07:00–19:00) or 14-h light/8-h dark (mice
lights on 06:00–20:00) cycle. Animals were provided water and
chow ad libitum. All rats and mice used were male and aged
8–16 wks. Experiments were carried out in accordance with the
Institutional Animal Care and Use Committee at the University
of Kentucky (Approved Protocol # 2009–0486). All efforts were
made to minimize animal suffering, to reduce the number of
animals used, and to utilize alternatives to in vivo techniques, in
accordance with the International Association for the Study of
Pain (Zimmermann, 1983) and the National Institutes of Health
Office of Laboratory Animal Welfare Guide for the Care and Use
of Laboratory Animals.
Behavioral pharmacology experiments were performed by an
observer blinded to subject grouping and treatment. Blinding was
accomplished by having a second person perform intraplantar
injections and keep track of subject grouping.
Drug Administration and Materials
A 30 gauge ½′′ needle attached to a Hamilton microsyringe
was used to administer drug solutions to unanesthetized mice
by intrathecal (5–10 µL) or intraplantar (5–25 µL) injection.
Mice were unanesthetized so that pain-like behaviors could
be measured immediately following drug injections; therefore,
efforts were made to minimize pain and distress by lightly
restraining the mice using a cloth to isolate either the lumbar
vertebrae or the ankle and hindpaw and performing injections
as quickly and accurately as possible. Importantly, experimenters
performing intrathecal injections in unanesthetized mice were
first rigorously trained using anesthetized mice. Intrathecal
injections were performed by isolating the L4/L5 spinal processes,
inserting the needle into the intervertebral space, and confirming
correct location by the evocation of a reflexive tail or hindpaw
flick before slowly depressing the plunger on the microsyringe
(Hylden and Wilcox, 1980; Fairbanks, 2003). Intrathecal or
intraplantar injections into unanesthetized mice were approved
by an ethical standards committee as described in the Animals
section.
Methylglyoxal (MG; M0252, Sigma-Aldrich, St. Louis, MO)
was diluted in 0.9% sterile saline for intraplantar (0–1,000
µg) injection. Stock solutions of MG contain trace amounts
(<1%) of formalin, an agonist at TRPA1 (McNamara et al.,
2007); however, electrophysiological studies in primary cerebellar
granule neurons indicate no functional difference between
commercial MG purchased from Sigma-Aldrich and synthesized
pure MG (Distler et al., 2012). HC030031 (HC; Cat. No. 2896,
Tocris, Minneapolis, MN) was diluted in ethanol and Tween-80
before the stepwise addition of saline and adjusted to a pH 7.4
prior to intrathecal injection (0–10 µg).
Pain-like Behavior
Fluctuations in noise, vibrations, temperature, and other
environmental variables in the behavioral testing room were
minimized to optimize reliable measurements between cohorts
of animals tested on different days. Animals were acclimated to
each behavioral testing environment for 1 h at least 1 d prior to
commencing studies and then again for 30–60min on each day
of testing.
Licking/Lifting Nociceptive Responses
Immediately following intraplantar injection of saline or
methylglyoxal, animals were placed within an acrylic enclosure
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on top of a clear, plastic surface. A mirror was positioned below
the enclosure to facilitate quantification of licking, lifting, and
flinching. Responses of the injected hindpaw were quantified for
5min. One rapid flinch was equated to 1 s of licking or lifting and
the sum of these pain-related responses is henceforth referred to
as the number of licking/lifting nociceptive responses.
Heat Hypersensitivity
Animals were placed on a heated surface (52.5 ± 1◦C) within an
acrylic enclosure (Hotplate; Columbus Instruments, Columbus,
OH). The time until hindpaw withdraw response (e.g., jumping,
licking, flinching) was recorded. The animal was immediately
removed after paw withdraw or a cutoff of 30 s to avoid tissue
injury. Three trials were averaged for each time point with a
between-trial interval of at least 1min.
Mechanical Hypersensitivity
Animals were placed within a rectangular acrylic box with
opaque walls (15 × 4 × 4 cm) on a steel mesh grid. The plantar
surface of the ventral-medial hindpaw was stimulated with an
incremental series of 8 von Frey monofilaments (Stoelting, Inc.,
Wooddale, IL) of logarithmic stiffness using a modified up-down
method (Dixon, 1980; Chaplan et al., 1994), as previously
described (Griggs et al., 2015b). The calculated 50% withdraw
threshold is reported.
Conditioned Place Avoidance (CPA)
CPA testing in the current study was similar to our previously
published method of inducing conditioned place preference
with a first-line agent used clinically for diabetic neuropathic
pain, gabapentin (Griggs et al., 2015a) with the following
modifications. We used a three-chambered acrylic enclosure
with manual doors and the time spent in each chamber
was quantified using a 4 × 16 photobeam array (Place
Preference, San Diego Instruments, San Diego, CA; http://www.
sandiegoinstruments.com/place-preference/). Printed paper was
used to cover the outside of the clear box so that the middle
chamber was gray and the end chambers had either vertical
or horizontal black and white stripes that were ¾′′ wide. Mice
were acclimated to the CPA box on habituation days 1–2 and
then preconditioning preferences were assessed on d3. During
conditioning on d4, intraplantar saline injection-pairing in the
morning was followed by methylglyoxal (300 µg) injection-
pairing to the opposite chamber in the afternoon. On d5, the
same conditioning procedure was repeated with methylglyoxal
injected into the hindpaw that received saline on d4, and visa-
versa. Drug-chamber pairings and the hindpaw initially receiving
methylglyoxal were counterbalanced. On d6, postconditioning
preferences were assessed in the absence of any injections. A
difference score was calculated by subtracting the time spent in a
chamber during preconditioning from the time spent in the same
chamber during postconditioning.
p-ERK Quantification via
Immunohistochemistry
We measured the number of cell profiles displaying p-ERK
immunofluorescence in the superficial dorsal horn after
administration of MG to the hindpaw. Animals were injected
with intraplantar saline or methylglyoxal, licking and lifting
responses were quantified, and then mice were anesthetized
with isoflurane (5% induction, 2% maintenance). Ten minutes
after intraplantar injection, animals were perfused through the
left ventricle with room temperature 1x phosphate buffered
saline (PBS) with heparin (10,000 USP units/L) followed by
ice-cold fixative (10% phosphate buffered formalin). The
lumbar spinal cord was removed and postfixed overnight in
10% phosphate buffered formalin and then cryoprotected in
30% sucrose in 0.1M PBS for several days. Transverse sections
(30µm) surrounding L4 were cut on a freezing microtome and
collected in PBS. The sections were washed three times in PBS
and then pretreated with blocking solution (3% normal goat
serum and 0.3% Triton X-100 in PBS) for 1 h. Sections were
then incubated in blocking solution containing the primary
antibody rabbit anti-p-ERK (1:500, Cell Signaling Technology
#4370 RRID:AB_2315112) overnight at room temperature on a
slow rocker. The sections were washed three times in PBS, and
incubated in goat anti-rabbit secondary antibody (1:800, Alexa
Fluor 568, Invitrogen A11011, RRID:AB_143157) for 90min,
washed in PBS then 0.01M phosphate buffer without saline,
mounted onto Superfrost Plus slides, air dried, and cover-slipped
with Prolong Gold with DAPI mounting medium (Invitrogen
P36931).
All images were captured on a Nikon Eclipse TE2000-E
microscope using a 10x objective and analyzed using NIS-
Elements Advanced Research software. We focused our
quantification of the number of p-ERK immunopositive
cell profiles within lamina I–II, where the majority of
nociceptive peripheral afferents terminate within the
dorsal horn (Corder et al., 2010). An observer blinded to
treatment quantified and then averaged 4–6 high quality
randomly selected sections of lumbar spinal cord from each
animal.
Data Analysis and Statistics
Licking/lifting behaviors after intraplantar MG were analyzed
using one-way ANOVA followed by Holm-Sidak multiple
comparison correction. For testing the dose-dependency of MG-
evoked pain-like behaviors, there was no difference between the
saline controls in any of the multiple cohorts of animals tested
alongside different doses of MG. Therefore, the saline controls
for each dose of MG were combined, resulting in a larger sample
size. Licking/lifting behaviors and p-ERK immunohistochemistry
in TRPA1−/−, AC1−/−, or after HC030031 administration
were analyzed using two-way ANOVA followed by Holm-
Sidak multiple comparison correction. Conditioned place
avoidance (CPA) difference scores were analyzed using unpaired,
homoscedastic t-test. Mechanical and heat hypersensitivity in
wild-type, TRPA1−/−, and AC1−/− mice were analyzed using a
repeated measures two-way ANOVA followed by a Holm-Sidak
multiple comparison correction. A value of α = 0.05 was used
to determine statistical significance. All data were analyzed using
Prism 7.0 (GraphPad, La Jolla, CA) and are presented as mean±
SEM.
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RESULTS
Methylglyoxal Is Sufficient to Produce
Multiple Behavioral Signs of Hyperalgesia
and Affective Pain
We evaluated pain-like outcomes after peripheral MG
administration using a battery of behavioral tests, including MG-
evoked licking and lifting responses, mechanical hypersensitivity,
heat hypersensitivity, and CPA, a behavioral measure of negative
pain affect in rodents (Johansen et al., 2001). This is novel,
because previous studies investigating MG-evoked painful
sensitization did not assess mechanical hypersensitivity or
affective pain—both of which are prevalent symptoms of diabetic
pain.
As illustrated in Figures 1A,B, MG dose-dependently evoked
licking and lifting responses in rats [F(2,9) = 6.87; p= 0.015] and
mice [F(7,41) = 88.2; p < 0.0001]. Figure 1C indicates that MG-
evoked nociceptive responses lasted 1 h [drug × time; F(15,90)
= 3.4; p = 0.0002]. The cumulative number of nociceptive
responses during the first 5min after administration of 1,000 µg
MG is summarized in Figure 1B. As illustrated in Figures 1D,E,
MG decreased mechanical withdraw thresholds [drug × time;
F(5,85) = 3.54; p= 0.0059] and heat response latencies [drug dose
× time; F(15,100) = 5.0; p < 0.0001] in mice.
FIGURE 1 | Intraplantar methylglyoxal administration is sufficient to produce behavioral signs of nociception, hyperalgesia, and affective pain. We administered
methylglyoxal (MG) by the intraplantar (i.pl.) route and then measured pain-like behaviors. Total number of licking or lifting nociceptive responses over 5min in (A) rats
or (B) mice. (C) Duration of nociceptive responses evoked by i.pl. MG in mice. Changes in (D) mechanical withdraw thresholds or (E) heat response latencies after
i.pl. administration of MG in mice. (F) Difference scores indicating conditioned place avoidance (CPA) in mice after i.pl. MG (300 µg; n = 8), calculated as the
postconditioning minus preconditioning time spent in the saline or MG paired chamber. ⋆p < 0.05 vs. Saline. (a–c) p < 0.05 vs. Saline for MG 10 µg (a), MG 30 µg
(b), MG 100 µg (c). n shown above the bar graphs in (A,B) and in the legend in (C,E).
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In contrast to conventional measurement of stimulus-evoked
hypersensitivity using von Frey filaments or a hotplate, CPA is an
index of the aversive quality of spontaneous pain in the absence
of an evoking stimulus. We reasoned that if MG administration
is aversive, then mice would avoid the location associated with
the negative affect produced byMG. Tomeasure this MG-evoked
affective pain, we used a three-chambered place conditioning
apparatus to determine CPA induced by a 2-day conditioning
paradigm to intraplantar MG. Baseline preconditioning times
spent in the saline-paired (mean ± SEM; 334.7 ± 38.9 s) or
MG-paired (354.2 ± 42.35 s) chambers were similar [p = 0.75].
Postconditioning time spent in the MG-paired chamber (273.9 s
± 38.6) was less than time spent in the saline-paired chamber
(489.6 s ± 49.9) [p = 0.0026]. As illustrated in Figure 1F, the
difference score for MG [−80.36 ± 42.4 s] was less than that for
saline [154.9± 38.9 s; p= 0.02]. Production of CPA suggests that
MG induces a state of negative pain affect.
Methylglyoxal-Evoked Spinal Sensitization
and Pain-Like Behavior Requires TRPA1
To determine the contribution of spinal TRPA1 to MG-
evoked pain-like behavior and activation of spinal neurons, we
measured not only nociceptive responses as previously reported
(Andersson et al., 2013; Huang et al., 2016), but also heat
hypersensitivity and p-ERK immunostaining after genetic or
pharmacological disruption of TRPA1. Intraplantar MG was
administered to either TRPA1+/+ and TRPA1−/− mice or to
wild-type mice that were pre-treated intrathecally with vehicle
or HC030031 30min before i.pl. MG. Figures 2A,B show
representative images of p-ERK positive profiles in lamina I-II
of the lumbar spinal cord dorsal horn. Figure 2C illustrates that,
compared to intraplantar saline administration, MG increased p-
ERK in TRPA1+/+ [p < 0.0001] and after intrathecal injection of
vehicle [p < 0.0001]. By contrast, MG did not increase p-ERK in
TRPA1−/− [p= 0.95] nor after intrathecal injection of HC030031
[p = 0.088]. Thus, compared to wild-type or vehicle control
mice, both global TRPA1 knockout [genotype × MG; F(1,11) =
48.41; p < 0.0001] and inhibition of spinal TRPA1 [antagonist
× MG; F(1,12) = 67.02; p < 0.0001] attenuated MG-evoked
p-ERK. Figure 2D illustrates that, compared to intraplantar
saline administration, MG produced acute licking and lifting
nociceptive responses in TRPA1+/+ [p < 0.0001] mice and mice
administered intrathecal vehicle [p < 0.0001]. Importantly, MG-
evoked nociceptive responses in TRPA1−/− or after intrathecal
HC030031 administration were diminished when compared to
TRPA1+/+ [p < 0.0001] or intrathecal vehicle [p < 0.0001]
controls, respectively. Thus, compared to TRPA1+/+ or vehicle
control mice, both global TRPA1 knockout [strain×MG; [F(1,14)
= 44.66; p < 0.0001] and inhibition of spinal TRPA1 [antagonist
× MG; F(1,19) = 29.57; p < 0.0001] attenuated MG-evoked
nociceptive responses. Figure 2E illustrates that, compared to
saline, MG decreased heat response thresholds in wild-type but
not TRPA1−/− mice [strain × time; F(5,45) = 10.67; p < 0.0001].
Compared to TRPA1−/− and saline controls, heat response
thresholds in wild-types administered MG were reduced at
30min [p < 0.0001]. As illustrated in Figure 2F, MG decreased
heat response latencies in wild-type mice after intrathecal
administration of vehicle but not HC030031 [antagonist × time;
F(3,18) = 7.09; p = 0.002]. Importantly, HC030031 blocked the
decrease in heat response latencies in intrathecal vehicle mice at
20–40min after intraplantar MG administration [p < 0.05].
Methylglyoxal-Evoked Pain-Like
Hypersensitivity Requires AC1
TRPA1 fine tunes mechanical sensitivity (Kwan et al., 2009;
Brierley et al., 2011) andmediates various forms of cold sensation
(Story et al., 2003) and chemosensation (Bautista et al., 2005;
McNamara et al., 2007; Trevisani et al., 2007; Eberhardt et al.,
2012). There is little evidence to suggest that TRPA1 directly
mediates heat sensation, thus MG-TRPA1 activity likely recruits
an additional mechanistic component. One possibility is that
AC1-mediated synaptic plasticity in the dorsal horn (Xia and
Storm, 1997; Zhuo, 2012) provides a functional link between
primary nociceptors containing TRPA1 and those that contain
the canonical heat sensor, transient receptor potential vanilloid
type 1 (TRPV1) (Fischer et al., 2014; Spahn et al., 2014; Weng
et al., 2015). To test this hypothesis, we evaluated MG-evoked
nociception and hyperalgesia in AC1 knockout mice.
As illustrated in Figure 3A, MG (30 µg) decreased heat
response latencies in wild-type mice [drug × time in AC1+/+;
F(5,30) = 8.72; p < 0.0001] at 30–60min [p < 0.001]. By
contrast, MG did not change heat response latencies in AC1−/−
[drug × time in AC1−/−; F(5,30) = 1.12; p = 0.37]. Similarly,
Figure 3B illustrates that MG had no effect on mechanical
withdraw thresholds in AC1−/− at any timepoint measured
[drug × time in AC1−/−; F(5,35) = 0.575; p = 0.72]. Figure 3C
illustrates that, compared to saline, intraplantar MG produced
licking and lifting responses [drug; F(1,14) = 193.6; p < 0.0001]
in wild-type [vs. saline; p < 0.0001] and AC1−/− [p <
0.0001] mice. The number of MG evoked licking and lifting
responses was similar between wild-type and AC1−/− mice
after saline [p = 0.99] or MG administration [p = 0.99],
consistent with the lack of effect of AC1 knockout on formalin-
induced increases in spinal p-ERK expression (Wei et al., 2006).
These results indicate that AC1 mediates delayed heat and
mechanical hypersensitivity but not nociceptive behaviors during
the initial 0–5min phase after intraplantar MG administration.
This is in agreement with a previous study showing AC1 gene
deletion did not block nociception during the initial phase after
intraplantar administration of formalin (Wei et al., 2002), which
is also a TRPA1 agonist (McNamara et al., 2007). These results
suggest that AC1 may not be important for TRPA1-mediated
chemosensation in peripheral nociceptors.
DISCUSSION
Methylglyoxal Is Sufficient to Produce Not
Only Immediate Nociception and Delayed
Hyperalgesia, But Also Affective Pain
Our results rigorously characterize a rodent model that
recapitulates neuropathic pain symptoms of diabetic patients.
Administration of MG to rodents is sufficient to produce several
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FIGURE 2 | Methylglyoxal-induced activation of dorsal horn neurons requires TRPA1. (A,B) Representative images showing immunofluorescent localization of
phosphorylated extracellular signal-regulated kinase (p-ERK) in cell profiles of the lumbar spinal cord dorsal horn. These images illustrate p-ERK after intraplantar (i.pl.)
injection of methylglyoxal (MG; 30 µg) to wild-type (+/+) or TRPA1 knockout (-/-) mice or wild-type mice pretreated with intrathecal (i.t.) injection of the TRPA1
antagonist HC030031 (HC) or its vehicle (Veh) control. Quantification of (C) the # of p-ERK+ cell profiles (n = 4) at 10min and (D) licking and lifting nociceptive
responses (n = 4–8) at 0–5min after i.pl. administration of MG. Heat response latencies after i.pl. injection of MG in (E) TRPA1 knockouts (n = 4–7) or (F) after
pretreatment with i.t. HC030031 (n = 4). ⋆p < 0.05 vs. all other groups.
behavioral signs of pain. Consistent with previous reports, we
observed nociception (paw licking and lifting responses) in mice
(Andersson et al., 2013) and rats (Huang et al., 2016). We go
beyond previous reports, showing that MG-induced nociception
was dose-dependent, persisted for 1 h at the highest dose of MG
tested (1,000 µg), and was complemented by a dose-dependent
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FIGURE 3 | AC1 is required for MG-induced heat and mechanical hyperalgesia but not immediate pain-like behaviors. (A) Heat response latencies (n = 4),
(B) mechanical withdraw thresholds (n = 4–10), and (C) nociceptive responses (n = 4–5) after intraplantar (i.pl.) administration of MG (30 µg) in AC1 knockout (-/-)
mice and their wild-type controls (+/+). ⋆p < 0.05 vs. all other groups. #p < 0.05 as indicated.
decrease in heat response thresholds. In addition, we show for
the first time that MG is sufficient to elicit not only mechanical
hypersensitivity, but also CPA, a proxy measure of negative
pain affect in rodents (Sufka, 1994; Johansen et al., 2001;
Tzschentke, 2007; King et al., 2009; King and Porreca, 2014).
In addition to MG, other TRPA1-activating compounds such as
formalin, acrolein, or AITC also produce behavioral avoidance
in mice, a phenomenon that is absent in TRPA1 knockout
animals (Yonemitsu et al., 2013). Therefore, it is tempting to
speculate that TRPA1 mediates the production of CPA by MG.
Nevertheless, our discovery that MG is sufficient to produce
affective pain is particularly important, because continuous or
paroxysmal spontaneous pain are a major burden to diabetic
patients with pain. We conclude that intraplantar administration
of MG could be a useful model to study the mechanisms of
painful diabetic neuropathy.
The mechanism of MG-evoked pain might involve its well-
known ability to promote the generation of advanced glycation
end-products (AGEs). AGEs are sufficient to induce mechanical
hypersensitivity (Liu et al., 2017), likely through the receptor for
AGEs (RAGE). RAGE specifically recognizes MG-AGEs (Xue
et al., 2014) and is involved in diabetic neuropathy (Toth et al.,
2008) and MG-evoked spinal sensitization (Wei et al., 2017).
Chronic intrathecal administration of MG produced mechanical
hypersensitivity and increased AGE levels in the DRG (Liu et al.,
2017). However, these studies implicating MG and AGEs in the
production of pain sensitization occurred on a timescale of days
to weeks, much longer than the early-onset pain-like responses
measured in the current study.MG scavengers such asmetformin
or aminoguanidine are known to reduce the formation of AGEs
(Rahbar et al., 2000; Kender et al., 2014; Kinsky et al., 2016),
and Huang et al. showed that these AGE breakers did not alter
early-onset nociception induced by intraplantar administration
of MG (Huang et al., 2016). In summary, we speculate that
MG-derived AGEs may be important for hyperalgesia during
conditions of chronic MG elevation (e.g., PDN), but not for the
early-onset pain-like behaviors in the current study.
Altered expression and/or function of Nav1.8 may mediate
MG-evoked pain at timepoints beyond those tested in the
current study. Huang et al. found that a Nav1.8 inhibitor
reduced pain-like behaviors at 10–60min, but not 0–5min, after
intraplantar administration of MG (Huang et al., 2016). Bierhaus
et al. indicate that Nav1.8 is required for heat hyperalgesia
and depolarization of DRG neuron resting membrane potential
induced by MG at 3 h after its administration. These results
suggest that Nav1.8 can be targeted to reduce MG-evoked
hyperalgesia; however, the 3 h time course of Nav1.8 action—
reported by Huang et al. and Bierhaus et al.—is not sufficient to
explain either the early-onset MG-evoked nociception (0–5min)
or the hyperalgesia (15–120min) that we report here. Changes
in Nav1.8 gene expression likely require hours to days, and
so functionally-relevant changes in Nav1.8 protein expression
within the 5–120min period after MG administration seems
unlikely. Future investigations linking MG-induced nociception
and hyperalgesia to Nav1.8 physiology are needed.
Previous studies suggest that neuropeptides associated
with neurogenic inflammation may mediate MG-induced
nociceptive responses. For example, systemic administration
of MG potentiates the KCl or heat-induced release of the
neuropeptide CGRP from hindpaw skin (Bierhaus et al., 2012).
Furthermore, TRPA1 knockout or co-application of HC030031
blocks MG-evoked CGRP release in sciatic nerve and at
peripheral nerve terminals in a hairy skin preparation (Eberhardt
et al., 2012). This is consistent with our current results indicating
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that TRPA1 is required for MG-evoked nociceptive responses
and spinal p-ERK. We suggest that MG-TRPA1 activity results
in neuropeptide release, leading to early-onset nociceptive
behaviors, and the downstream activation of ERK in second
order neurons of the dorsal horn. Future studies are needed to
definitively determine changes in DRG neurons or peripheral
nerve that mediate the early-onset nociceptive response induced
by MG.
Methylglyoxal Activates Nociresponsive
Neurons in the Spinal Cord Dorsal Horn
ERK activation in the spinal cord dorsal horn is a marker
of central sensitization. We report that nociceptive responses
induced by MG (0–5min) precede increased p-ERK in the spinal
cord (10min) and behavioral hyperalgesia (15min); this suggests
that ERK activationmediates prolonged hyperalgesia but perhaps
not early-onset nociceptor hyperexcitability. The increase in
p-ERK in the dorsal horn is consistent with spinal ERK
activation in animal models of painful diabetic neuropathy with
elevated circulatingMG, including streptozotocin administration
(Daulhac et al., 2006; Tsuda et al., 2008; Huang et al., 2016), db/db
mice (Tsuda et al., 2008; Bierhaus et al., 2012; Dauch et al., 2012;
Xu et al., 2014), and ZDF rats (Griggs et al., 2016). Indeed, spinal
administration of a MEK inhibitor reduced pain-like behavior
and spinal p-ERK in streptozotocin rats (Tsuda et al., 2008) and
db/db mice (Xu et al., 2014). These results highlight the role of
spinal p-ERK in the production of hyperalgesia in painful diabetic
neuropathy. Importantly, our results suggest that peripheral MG
administration is sufficient to activate nociresponsive pathways
in the spinal cord that are elevated in rodent models of type 1 and
type 2 painful diabetic neuropathy.
TRPA1 Mediates Methylglyoxal-Evoked
Pain-Like Behaviors and Spinal
Sensitization
TRPA1 is required for MG-evoked signs of pain transmission.
Our results demonstrate that in addition to blocking MG-
evoked nociception as previously reported (Andersson et al.,
2013; Huang et al., 2016), both pharmacological and genetic
disruption of spinal TRPA1 also attenuated intraplantar MG-
evoked hyperalgesia and spinal ERK activation. Our results
go beyond previous MG studies that blocked only peripheral
TRPA1, by administering a TRPA1 antagonist via the intrathecal
route. This is consistent with the reduction in pain-like behaviors
after intrathecal administration of the TRPA1 antagonist
Chembridge-5861528 in streptozotocin-treated rats (Wei et al.,
2009, 2010) with elevated MG (Huang et al., 2016). Similarly,
the development of pain-like behavior after chronic inhibition
of the major metabolic enzyme for MG, glyoxalase 1, in wild-
type mice is absent in TRPA1 knockout mice (Andersson
et al., 2013). We conclude that TRPA1 is required not only for
the pain-like behavior and activation of spinal nociresponsive
neurons produced by exogenous MG, but also may mediate the
pronociceptive actions of endogenous MG in conditions where
MG is elevated, such as in painful diabetic neuropathy or after
inhibition of glyoxalase 1.
The Site of Action of TRPA1 May Include
the Central Terminals of Primary Afferent
Neurons
Several lines of evidence suggest that pain is mediated by
MG-TRPA1 activity at the presynaptic, central terminals of
primary sensory neurons. (1) Application of the TRPA1
agonists AITC (Kosugi et al., 2007), cinnemaldehyde (Uta
et al., 2010), or MG (Wei et al., 2017) to spinal cord slices
increased the frequency of spontaneous miniature excitatory
postsynaptic currents, suggesting a presynaptic mechanism of
potentiated neurotransmitter release. (2) Spinal administration
of cinnemaldehyde (Wei et al., 2011) or MG (Liu et al.,
2017; Wei et al., 2017) produced hypersensitivity at the
hindpaw. (3) Spinal administration of the TRPA1 antagonists
Chembridge-5861528 (Wei et al., 2011) or HC030031 (current
results) reduced hypersensitivity after activation of peripheral
TRPA1 by intraplantar formalin or MG, respectively. (4)
Immunohistochemical expression of TRPA1 in the spinal
dorsal root may indicate protein transport to central terminals
(Anand et al., 2008), indicating that TRPA1 is available for
modulating synaptic transmission. Lastly, the importance of a
spinal MG-TRPA1 mechanism is emphasized by the finding
that the analgesic potency of TRPA1 antagonism in type 1
diabetic animals is 10-fold higher upon intrathecal, compared
to intraplantar, administration (Wei et al., 2010). In summary,
we speculate that presynaptic TRPA1 on the central terminals
of primary afferents, as opposed to receptors located on second
order dorsal horn neurons, is required for MG-evoked pain.
Methylglyoxal-Evoked Hyperalgesia
Requires AC1
AC1 is a critical mediator of CNS neuron plasticity and the
transition to chronic pain (Zhuo, 2012; Taylor and Corder, 2014).
To our knowledge, we are the first to implicate a role for adenylyl
cyclase in MG-evoked pain. AC1 gene deletion abolished heat
and mechanical hypersensitivity during the delayed phase, at
30min after MG administration. Several current and previous
results suggest that a signaling link between TRPA1 and the AC1
isoformmediates MG-evoked pain. (1) Genetic deletion of either
TRPA1 or AC1 reduced MG-evoked hyperalgesia in the current
results. (2) AC1 mediates the TRPA1-induced sensitization of
DRG neurons to subsequent chemogenic stimulation (Spahn
et al., 2014). (3) Genetic deletion of AC1 attenuates the delayed
phase of formalin-induced nociception (Wei et al., 2002). These
results taken together lead us to conclude that a TRPA1-
AC1 signaling mechanism drives pain-related sensitization and
delayed hyperalgesia after MG administration.
Spinal AC1 may contribute to signs of MG-evoked painful
sensitization. For example, AC1mediates mechanisms of chronic
pain sensitization in the spinal cord such as ERK activation
(Wei et al., 2006), CREB activation (Wang and Zhuo, 2002;
Feng et al., 2016), the reinstatement of pain after recovery
from inflammatory injury (Corder et al., 2013), and long-term
potentiation (Wang et al., 2011). In Zucker Diabetic Fatty rats,
intrathecal administration of SQ22536, a non-specific adenylyl
cyclase inhibitor, reduced pain-like behavior, and spinal levels
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of the adenylyl cyclase signaling molecules cAMP, p-PKA, and
p-CREB (Feng et al., 2016). Elevated MG levels in Zucker
Diabetic Fatty rats (Griggs et al., 2016) leads us to speculate that
MG may induce AC1-dependent spinal sensitization in type 2
painful diabetic neuropathy. This speculation is supported by
another study showing that electrical stimulation of the sciatic
nerve resulted in long-term potentiation only when exogenous
MG was applied to the spinal cord dorsal horn (Wei et al.,
2017). Furthermore, pharmacological blockade of AC1 by NB001
abolishes long-term potentiation in the spinal cord (Wang et al.,
2011). However, AC1 knockout did not reduce MG-evoked
nociceptive responses in the current results. These results taken
together support our conclusion that AC1 mediates the spinal
sensitization that is responsible for MG-evoked hyperalgesia
in diabetes, but may not mediate the immediate nociceptive
behaviors induced by acute MG administration. Future studies
could test whether pharmacological inhibition of spinal AC1,
such as by NB001 or the recently discovered small molecule
inhibitor ST034307 (Brust et al., 2017), reduces neuropathic pain
in a model of MG-evoked pain.
Methylglyoxal Administration Is a Model of
Painful Diabetic Neuropathy
Additional knowledge of the molecular mechanisms of diabetic
pain is needed to develop better treatments for painful diabetic
neuropathy, which affects one-third of diabetes patients (Davies
et al., 2006; Abbott et al., 2011; Lee-Kubli et al., 2014).
Studies in the streptozotocin (Bierhaus et al., 2012), db/db
(Bierhaus et al., 2012), and ZDF (Griggs et al., 2016) rodent
models of diabetes as well as in diabetic patients (Bierhaus
et al., 2012; Sveen et al., 2013) indicate that elevated MG
is associated with neuropathic pain. Our results indicate that
intraplantar administration of MG produced dose-dependent
nociception, hyperalgesia, and affective pain. Importantly, MG
elicited evidence of spinal sensitization, which may contribute
to pain in diabetic patients (Vincent et al., 2011; Coppini,
2016). Furthermore, disruption of either TRPA1 or AC1
attenuated MG-evoked hyperalgesia in the current results,
and is sufficient to reduce hyperalgesia in rodent models of
diabetes where MG is elevated. This validates that intraplantar
administration of MG recapitulates mechanisms of painful
diabetic neuropathy, at least in animal models. We suggest
that MG administration could be an alternative approach to
the streptozotocin model to study the mechanisms of painful
diabetic neuropathy, as streptozotocin directly activates TRPA1
(Andersson et al., 2015) and depletes resident immune cells
in the PNS (Hidmark et al., 2017) to produce hyperalgesia
before the development of hyperglycemia. We conclude that MG
produces pain through a TRPA1-AC1 signaling pathway, and
suggest that future studies of novel therapeutics targeting TRPA1
or AC1 may benefit from an intraplantar MG administration
model that recapitulates multiple behavioral signs and molecular
mechanisms of painful diabetic neuropathy that are downstream
of elevated MG.
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